Allison Gaudy

659 total citations
25 papers, 338 citations indexed

About

Allison Gaudy is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Allison Gaudy has authored 25 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Hematology and 9 papers in Oncology. Recurrent topics in Allison Gaudy's work include Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (6 papers) and Acute Myeloid Leukemia Research (4 papers). Allison Gaudy is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (6 papers) and Acute Myeloid Leukemia Research (4 papers). Allison Gaudy collaborates with scholars based in United States, United Kingdom and Germany. Allison Gaudy's co-authors include Robert A. Mooney, Robert H. Pierce, Nico van Rooijen, Pilar Lardelli, Lisa M. Kelly, Jesús F. San Miguel, Kristen Hege, Paula Rodríguez‐Otero, Javier de la Rubia and Enrique M. Ocio and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Allison Gaudy

25 papers receiving 332 citations

Peers

Countries citing papers authored by Allison Gaudy

Since Specialization

Citations

This map shows the geographic impact of Allison Gaudy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Gaudy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Gaudy more than expected).

Fields of papers citing papers by Allison Gaudy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Gaudy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Gaudy. The network helps show where Allison Gaudy may publish in the future.

Co-authorship network of co-authors of Allison Gaudy

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Gaudy. A scholar is included among the top collaborators of Allison Gaudy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Gaudy. Allison Gaudy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology 2024 ·Clinical Pharmacology & Therapeutics ·Mohamed Elmeliegy, Joseph Chen, Aruna Dontabhaktuni, Allison Gaudy, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	9
2	Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial 2024 ·Pediatric Blood & Cancer ·Franco Locatelli, (unknown), Irene Schmid, Julián Sevilla, Owen Smith, Marry M. van den Heuvel‐Eibrink, Marco Zecca, C. Michel Zwaan, Allison Gaudy, Meera Patturajan, Jennifer Poon, Mathew Simcock, (unknown)	1
3	1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug–Drug Interaction Potential 2024 ·Drug Metabolism and Disposition ·Yongjun Xue, (unknown), Runlan Huo, Mu Chen, (unknown), Karen H. Dingley, Allison Gaudy, Jim X Shen	3
4	Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM). 2024 ·Journal of Clinical Oncology ·Suzanne Trudel, Nizar J. Bahlis, Rakesh Popat, María‐Victoria Mateos, Annette Juul Vangsted, Karthik Ramasamy, Joaquín Martínez‐López, Hang Quach, Robert Z. Orlowski, Joseph W. Burnett, Allison Gaudy, Wen‐Cong Chen, Jing Gong, (unknown), (unknown), Phillip J. Koo, (unknown), Jessica Katz, Paul G. Richardson	1
5	Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide 2023 ·Clinical Pharmacology in Drug Development ·Yiming Cheng, Allison Gaudy, Liangang Liu, Ying Ye, Michael A. Thomas, Yongjun Xue, Simon Zhou, Yan Li	1
6	Safety, Pharmacokinetics, and Antifibrotic Activity of CC‐90001 (BMS‐986360), a c‐Jun N‐Terminal Kinase Inhibitor, in Pulmonary Fibrosis 2023 ·Clinical Pharmacology in Drug Development ·Gerald Horan, Ying Ye, Mary Beth Adams, Anastasia Parton, (unknown), Shaojun Tang, Elizabeth A. Brown, Liangang Liu, (unknown), Leonidas N. Carayannopoulos, Allison Gaudy, Peter Schäfer, Maria Palmisano, Francisco Ramírez‐Valle	4
7	Population Pharmacokinetics of Oral Azacitidine, and Exposure–Response Analysis in Acute Myeloid Leukemia 2023 ·Clinical Pharmacology & Therapeutics ·Allison Gaudy, Eric Laille, (unknown), Simon Zhou, Barry Skikne, C.L. Beach	4
8	Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Fan Wu, Liangang Liu, Allison Gaudy, Xiaomin Wang, Leon Carayannopoulos, Michael Pourdehnad, Manisha Lamba	2
9	A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects 2023 ·Clinical Pharmacology Advances and Applications ·Yiming Cheng, Ying Ye, Allison Gaudy, Atalanta Ghosh, Yongjun Xue, Alice Wang, Simon Zhou, Yan Li	2
10	Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) 2022 ·Blood ·Isaac W. Boss, Ethan Thompson, Allison Gaudy, Minh Diem Vu, Colin D. Godwin, Michael R. Burgess, Sandy W. Wong, Luciano J. Costa	4
11	Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial 2020 ·Blood ·Dirk Reinhardt, Henrik Hasle, Karsten Nysom, André Baruchel, Franco Locatelli, (unknown), (unknown), Meera Patturajan, Mathew Simcock, Allison Gaudy, C. Michel Zwaan	1
12	Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects 2020 ·European Journal of Clinical Pharmacology ·Allison Gaudy, Christian Atsriku, Ying Ye, (unknown), Liangang Liu, Yongjun Xue, Sekhar Surapaneni, Maria Palmisano	13
13	First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator 2020 ·Clinical Pharmacology in Drug Development ·Ying Ye, Allison Gaudy, Peter Schäfer, Michael A. Thomas, Daniel Weiß, Nianhang Chen, Liangang Liu, Yongjun Xue, (unknown), Maria Palmisano	18
14	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial 2019 ·Blood ·Luciano J. Costa, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María‐Victoria Mateos, Enrique M. Ocio, Paula Rodríguez‐Otero, Jesús F. San Miguel, Shaoyi Li, R. Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac W. Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William Bensinger	132
15	Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs 2014 ·European Journal of Drug Metabolism and Pharmacokinetics ·John H. Wilton, Elena Kurenova, (unknown), Allison Gaudy, (unknown), Sandra Sexton, William G. Cance, Gerald J. Fetterly	4
16	Application of mechanism-based PKPD model to identify optimal dosing regimens for future development of oraxol. 2013 ·Journal of Clinical Oncology ·Gerald J. Fetterly, Allison Gaudy, Biao Liu, (unknown), (unknown), David Hangauer, Kyung-Mi Park, (unknown), Yung‐Jue Bang	1
17	Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients 2013 ·Blood ·Eunice S. Wang, Gerald J. Fetterly, William Brady, Wei Phin Tan, (unknown), Allison Gaudy, Carlos E. Vigil, Jason H. Mendler, Michael W. Becker, (unknown), Jane L. Liesveld, Meir Wetzler	5
18	Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor–deficient mouse 2011 ·Metabolism ·(unknown), Allison Gaudy, Teresa A. Zimmers, Leonidas G. Koniaris, Robert A. Mooney	7
19	Suppressor of Cytokine Signaling-3 Is a Glucagon-inducible Inhibitor of PKA Activity and Gluconeogenic Gene Expression in Hepatocytes 2010 ·Journal of Biological Chemistry ·Allison Gaudy, (unknown), Jean S. Campbell, Alan V. Smrcka, Robert A. Mooney	17
20	Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling 2009 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·(unknown), Allison Gaudy, Nico van Rooijen, Robert H. Pierce, Robert A. Mooney	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact